Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 33, 2012, Pages 13171-13176

  Geihe, Erika I ^a   Cooley, Christina B ^a   Simon, Jeff R ^a   Kiesewetter, Matthew K ^a   Edward, Justin A ^a   Hickerson, Robyn P ^b   Kaspar, Roger L ^a,b   Hedrick, James L ^c   Waymouth, Robert M ^a   Wender, Paul A ^a  

^a STANFORD UNIVERSITY   (United States)

^b TransDerm Inc   (United States)

^c IBM ALMADEN RESEARCH CENTER   (United States)

Author keywords

Amphipathic co oligomers; Biodegradable oligomers; Nanoparticles; Oligonucleotide delivery; Organocatalysis

Indexed keywords

CARBONIC ACID DERIVATIVE; ENHANCED GREEN FLUORESCENT PROTEIN; GUANIDINE; OLIGOCARBONATE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BIODEGRADATION; CATALYSIS; COMPLEX FORMATION; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHOBICITY; IN VITRO STUDY; MOLECULAR PROBE; OLIGOMERIZATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING;

BIOLOGICAL TRANSPORT; CARBONATES; CELL DEATH; CELLS, CULTURED; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; GUANIDINE; HUMANS; KERATINOCYTES; LIGHT; LYCOPERSICON ESCULENTUM; MICROSCOPY, FLUORESCENCE; RNA, SMALL INTERFERING; SCATTERING, RADIATION;

EID: 84865173768     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1211361109     Document Type: Article

References (38)

1. Leung KM, Whittaker PA (2005) RNA interference: From gene silencing to genespecific therapeutics. Pharmacol Ther 107:222-239.
2. Lares MR, Rossi JJ, Ouellet DL (2010) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28:570-579.
3. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK (2011) RNA interference in the clinic: Challenges and future directions. Nat Rev Cancer 11:59-67.
4. Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457:426-433.
5. Davidson BL, McCray PB (2011) Current prospects for RNA interference-based therapies. Nat Rev Genet 12:329-340.
6. Aagaard L, Rossi JJ (2007) RNAi therapeutics: Principles, prospects, and challenges. Adv Drug Deliv Rev 59:75-86. (Pubitemid 46770900)
7. Elbashir SM, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498. (Pubitemid 32494397)
8. Burnett JC, Rossi JJ, Tiemann K (2011) Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6:1130-1146.
9. Leachman SA, et al. (2010) First-in-human mutation-targeted siRNA phase 1b trial of an inherited skin disorder. Mol Ther 18:442-446.
10. Karkare S, Bhatnagar D (2006) Promising nucleic acid analogs and mimics: Characteristic features and applications of PNA, LNA, and morpholino. Appl Microbiol Biotechnol 71:575-586. (Pubitemid 44114786)
11. Bruno K (2011) Using drug-excipient interactions for siRNA delivery. Adv Drug Deliv Rev 63:1210-1226.
12. Hsu T, Mitragotri S (2011) Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc Natl Acad Sci USA 108:15816-15821.
13. Tan SJ, Kiatwuthinon P, Roh YH, Kahn JS, Luo D (2011) Engineering nanocarriers for siRNA delivery. Small 7:841-856.
14. Wang J, Lu Z, Wientjes MG, Au JLS (2010) Delivery of siRNA therapeutics: Barriers and carriers. AAPS J 12:492-503.
15. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG (2009) Lipid-based nanotherapeutics for siRNA delivery. J Int Med 267:9-21.
16. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 6:659-668.
17. Reischl D, Zimmer A (2009) Drug delivery of siRNA therapeutics: Potentials and limits of nanosystems. Nanomedicine 5:8-20.
18. Jeong JH, Mok H, Oh YK, Park TG (2009) siRNA conjugate delivery systems. Bioconjug Chem 20:5-14.
19. Liu Z, Tabakman S, Welsher K, Dai H (2009) Carbon nanotubes in biology and medicine: In vitro and in vivo detection, imaging, and drug delivery. Nano Res 2:85-120.
20. Eguchi A, et al. (2009) Efficient siRNA delivery into primary cells by peptide transduction- dsRNA binding domain. Nat Biotechnol 27:567-571.
21. Medarova Z, Pham W, Farrar C, Petkova V, Moore A (2007) In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 13:372-377. (Pubitemid 46376679)
22. Akhtar S, Benter IF (2007) Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 117:3623-3632. (Pubitemid 350224068)
23. Wender PA, et al. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporter. Proc Natl Acad Sci USA 97:13003-13008.
24. Wender PA, Cooley CB, Geihe EG (2012) Beyond cell penetrating peptides: Designed molecular transporters. Drug Discov Today Technol 9:e49-e55.
25. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH (2008) The design of guanidinium- rich transporters and their internalization mechanisms. Adv Drug Delivery Rev 60:452-472.
26. Cooley CB, et al. (2009) Oligocarbonate molecular transporters: Oligomerization-based syntheses and cell-penetrating studies. J Am Chem Soc 131:16401-16403.
27. Fukushima K, et al. (2008) Organocatalytic approach to amphiphilic comb-block copolymers capable of stereocomplexation and self-assembly. Biomacromolecules 9:3051-3056.
28. Kim SH, et al. (2011) Thermoresponsive nanostructured polycarbonate block copolymers as biodegradable therapeutic delivery carriers. Biomaterials 32:5505-5514.
29. Nederberg F, et al. (2011) Biodegradable nanostructures with selective lysis of microbial membranes. Nat Chem 3:409-414.
30. Pratt RC, Nederberg F, Waymouth RM, Hedrick JL (2008) Tagging alcohols with cyclic carbonate: A versatile equivalent of (meth)acrylate for ring-opening polymerization. Chem Commun 114-116. (Pubitemid 350264882)
31. Choi HS, Kim HH, Yang JM, Shin S (2006) An insight into the gene delivery mechanism of the arginine peptide system: Role of the peptide/DNA complex size. Biochim Biophys Acta 1760:1604-1612. (Pubitemid 44667276)
32. Hickerson RP, et al. (2011) Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenital model. J Invest Dermatol 131:1037-1044.
33. Gonzalez-Gonzalez E, et al. (2009) siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model. Gene Ther 16:963-972.
34. Smith FJ, et al. (2008) Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol 128:50-58. (Pubitemid 350249391)
35. Siprashvili Z, et al. (2003) Gene transfer via reversible plasmid condensation with cysteine-flanked, internally spaced arginine-rich peptides. Hum Gene Ther 14:1225-1233. (Pubitemid 37034572)
36. Knop K, Hoogenboom R, Fischer D, Schubert US (2010) Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives. Angew Chem Int Ed 49:6288-6308.
37. Gonzalez-Gonzalez E, et al. (2010) Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device. Mol Ther 18:1667-1674.
38. Prausnitz MR, Langer R (2008) Transdermal drug delivery. Nat Biotechnol 26:1261-1268.